HDM1005
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
Huadong Medicine · Phase 3 · Recruiting · Enrollment 825
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HDM1005 Cohort 1 | n/r | n/r | n/r | n/r |
| HDM1005 Cohort 2 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- HDM1005 Cohort 1: endpoint not reported
- HDM1005 Cohort 2: endpoint not reported
- Placebo: endpoint not reported